Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - HESKA CORPheska-09302018xex32x1.htm
EX-31.2 - EXHIBIT 31.2 - HESKA CORPheska-09302018xexx31x2.htm
EX-31.1 - EXHIBIT 31.1 - HESKA CORPheska-09302018xex31x1.htm
EX-10.2 - EXHIBIT 10.2 - HESKA CORPheska-09302018xex10x2.htm
EX-10.1 - EXHIBIT 10.1 - HESKA CORPheska-09302018xex10x1.htm




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________________ to _______________________
Commission file number: 0-22427
heskalogowhtbkgd07.jpg
HESKA CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
77-0192527
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)

3760 Rocky Mountain Avenue
Loveland, Colorado


80538
(Address of principal executive offices)
(Zip Code)

Registrant's telephone number, including area code: (970) 493-7272

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x   No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes x  No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.  See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer o
Accelerated filer x
Non-accelerated filer o
Smaller Reporting Company ¨
 
Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes o  No x
7,589,249 shares of the Registrant's Public Common Stock, $.01 par value, were outstanding at November 6, 2018.






TABLE OF CONTENTS
 
HESKA, ALLERCEPT, HEMATRUE, SOLO STEP, Element DC, Element HT5, Element POC, Element i, Element COAG and Element DC5x are registered trademarks and SonoSlate is a trademark of Heska Corporation. DRI-CHEM is a registered trademark of FUJIFILM Corporation. TRI-HEART is a registered trademark of Intervet Inc., d/b/a Merck Animal Health, formerly known as Schering-Plough Animal Health Corporation ("Merck Animal Health"), which is a unit of Merck & Co., Inc., in the United States and is a registered trademark of Heska Corporation in other countries. This quarterly report on Form 10-Q also refers to trademarks and trade names of other organizations.


- i-




PART I. FINANCIAL INFORMATION
Item 1. Financial Statements

HESKA CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
 
 
September 30,
 
December 31,
 
 
2018
 
2017
 
 
(unaudited)
 
 
ASSETS
Current assets:
 
 

 
 

Cash and cash equivalents
 
$
9,236

 
$
9,659

Accounts receivable, net of allowance for doubtful accounts of $234 and $215, respectively
 
13,647

 
15,710

Due from – related parties
 

 
1

Inventories, net
 
27,639

 
32,596

Lease receivable, current, net of allowance for doubtful accounts of $36 and $0, respectively
 
2,777

 
2,069

Contract acquisition costs, current
 
840

 
30

Other current assets
 
3,904

 
3,066

Total current assets
 
58,043

 
63,131

 
 
 
 
 
Property and equipment, net
 
16,284

 
17,331

Goodwill and intangible assets, net
 
28,349

 
28,645

Deferred tax asset, net
 
13,851

 
11,877

Lease receivable, non-current
 
11,521

 
9,615

Investments in unconsolidated affiliates
 
8,089

 

Contract acquisition costs, non-current
 
1,623

 
3

Other non-current assets
 
6,360

 
5,185

Total assets
 
$
144,120

 
$
135,787

 
 
 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
 
 

 
 

Accounts payable
 
$
4,545

 
$
9,489

Due to – related parties
 
280

 
1,828

Accrued liabilities
 
10,518

 
4,417

Current portion of deferred revenue
 
2,766

 
3,992

Line of credit and other short-term borrowings
 
6,019

 
6,000

Total current liabilities
 
24,128

 
25,726

 
 
 
 
 
Deferred revenue, net of current portion, and other
 
8,391

 
9,621

Total liabilities
 
32,519

 
35,347

Commitments and contingencies (Note 13)
 


 


 
 
 
 
 
Stockholders' equity:
 
 

 
 

Preferred stock, $.01 par value, 2,500,000 shares authorized, none issued or outstanding
 

 

Common stock, $.01 par value, 10,250,000 and 10,000,000 shares authorized, respectively, none issued or outstanding
 

 

Public common stock, $.01 par value, 10,250,000 and 10,000,000 shares authorized, 7,552,596 and 7,302,954 shares issued and outstanding, respectively
 
76

 
73

Additional paid-in capital
 
249,755

 
243,598

Accumulated other comprehensive income
 
216

 
232

Accumulated deficit
 
(138,446
)
 
(143,463
)
Total stockholders' equity
 
111,601

 
100,440

Total liabilities and stockholders' equity
 
$
144,120

 
$
135,787

See accompanying notes to condensed consolidated financial statements.

-1-




HESKA CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share amounts)
(unaudited)
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
2018
 
2017
 
2018
 
2017
Revenue:
 
 
 
 

 
 

 
 

Core companion animal health
 
$
27,190

 
$
25,578

 
$
80,652

 
$
75,453

Other vaccines, pharmaceuticals and products
 
3,765

 
4,758

 
12,729

 
17,847

Total revenue, net
 
30,955

 
30,336

 
93,381

 
93,300

 
 
 
 
 
 
 
 
 
Cost of revenue
 
16,161

 
16,783

 
52,215

 
51,609

 
 
 
 
 
 
 
 
 
Gross profit
 
14,794

 
13,553

 
41,166

 
41,691

 
 
 
 
 
 
 
 
 
Operating expenses:
 
 
 
 

 
 

 
 

Selling and marketing
 
6,215

 
5,815

 
18,299

 
17,908

Research and development
 
935

 
601

 
2,165

 
1,576

General and administrative
 
11,239

 
3,359

 
20,223

 
11,081

Total operating expenses
 
18,389

 
9,775

 
40,687

 
30,565

Operating (loss) income
 
(3,595
)
 
3,778

 
479

 
11,126

Interest and other (income) expense, net
 
(50
)
 
(6
)
 
37

 
(186
)
(Loss) income before income taxes
 
(3,545
)
 
3,784

 
442

 
11,312

Income tax expense (benefit):
 
 
 
 

 
 

 
 

Current income tax expense
 
27

 
8

 
56

 
25

Deferred income tax (benefit) expense
 
(1,902
)
 
693

 
(1,997
)
 
762

Total income tax (benefit) expense
 
(1,875
)
 
701

 
(1,941
)
 
787

 
 
 
 
 
 
 
 
 
Net (loss) income
 
(1,670
)
 
3,083

 
2,383

 
10,525

Net loss attributable to non-controlling interest
 

 

 

 
(498
)
Net (loss) income attributable to Heska Corporation
 
$
(1,670
)
 
$
3,083

 
$
2,383

 
$
11,023

 
 
 
 
 
 
 
 
 
Basic (loss) earnings per share attributable to Heska Corporation
 
$
(0.23
)
 
$
0.43

 
$
0.33

 
$
1.58

Diluted (loss) earnings per share attributable to Heska Corporation
 
$
(0.23
)
 
$
0.40

 
$
0.30

 
$
1.45

 
 
 
 
 
 
 
 
 
Weighted average outstanding shares used to compute basic (loss) earnings per share attributable to Heska Corporation
 
7,289

 
7,139

 
7,194

 
6,985

Weighted average outstanding shares used to compute diluted (loss) earnings per share attributable to Heska Corporation
 
7,289

 
7,668

 
7,820

 
7,580

 
See accompanying notes to condensed consolidated financial statements.


-2-




HESKA CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands) 
(unaudited)

 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Net (loss) income
 
$
(1,670
)
 
$
3,083

 
$
2,383

 
$
10,525

Other comprehensive income (loss):
 
 
 
 

 
 

 
 

Foreign currency translation
 
15

 
(45
)
 
(16
)
 
125

Comprehensive (loss) income
 
(1,655
)
 
3,038


2,367


10,650

 
 
 
 
 
 
 
 
 
Comprehensive loss attributable to non-controlling interest
 

 

 

 
(498
)
Comprehensive (loss) income attributable to Heska Corporation
 
$
(1,655
)
 
$
3,038


$
2,367


$
11,148

 
See accompanying notes to condensed consolidated financial statements.


-3-




HESKA CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(in thousands) 
(unaudited)

 
 
 
 
Common Stock
 
 
Additional
Paid-in
Capital
 
Accumulated
Other
Comprehensive
Income
 
 
 
Accumulated
Deficit
 
 
Total
Stockholders'
Equity
Three Months Ended September 30, 2017 and 2018
 
Shares
 
Amount
 
Balances, June 30, 2017
 
7,196

 
$
72

 
$
241,575

 
$
267

 
$
(145,339
)
 
$
96,575

Net income
 

 

 

 

 
3,083

 
3,083

Issuance of common stock, net of shares withheld for employee taxes
 
48

 

 
716

 

 

 
716

Stock-based compensation
 

 

 
707

 

 

 
707

Distribution for Heska Imaging minority interest
 

 

 

 

 
(9
)
 
(9
)
Other comprehensive loss
 

 

 

 
(45
)
 

 
(45
)
Balances, September 30, 2017
 
7,244

 
$
72

 
$
242,998

 
$
222

 
$
(142,265
)
 
$
101,027

 
 
 
 
 
 
 
 
 
 
 
 
 
Balances, June 30, 2018
 
7,498

 
$
75

 
$
246,422

 
$
201

 
$
(136,776
)
 
$
109,922

Net loss
 

 

 

 

 
(1,670
)
 
(1,670
)
Issuance of common stock, net of shares withheld for employee taxes
 
55

 
1

 
1,927

 

 

 
1,928

Stock-based compensation
 

 

 
1,406

 

 

 
1,406

Other comprehensive income
 

 

 

 
15

 

 
15

Balances, September 30, 2018
 
7,553

 
$
76

 
$
249,755

 
$
216

 
$
(138,446
)
 
$
111,601


 
 
 
 
Common Stock
 
 
Additional
Paid-in
Capital
 
Accumulated
Other
Comprehensive
Income
 
 
 
Accumulated
Deficit
 
 
Total
Stockholders'
Equity
Nine Months Ended September 30, 2017 and 2018
 
Shares
 
Amount
 
Balances, December 31, 2016
 
7,026

 
$
70

 
$
238,635

 
$
97

 
$
(151,827
)
 
$
86,975

Net income
 

 

 

 

 
10,525

 
10,525

Issuance of common stock, net of shares withheld for employee taxes
 
218

 
2

 
1,425

 

 

 
1,427

Stock-based compensation
 

 

 
2,093

 

 

 
2,093

Accretion of non-controlling interest
 

 

 
845

 

 

 
845

Distribution for Heska Imaging minority interest
 

 

 

 

 
(963
)
 
(963
)
Other comprehensive income
 

 

 

 
125

 

 
125

Balances, September 30, 2017
 
7,244

 
$
72

 
$
242,998

 
$
222

 
$
(142,265
)
 
$
101,027

 
 
 
 
 
 
 
 
 
 
 
 
 
Balances, December 31, 2017
 
7,303

 
$
73

 
$
243,598

 
$
232

 
$
(143,463
)
 
$
100,440

Adoption of accounting standards
 

 

 

 

 
2,634

 
2,634

Balances, January 1, 2018, as adjusted
 
7,303

 
73

 
243,598

 
232

 
(140,829
)
 
103,074

Net income
 

 

 

 

 
2,383

 
2,383

Issuance of common stock, net of shares withheld for employee taxes
 
250

 
3

 
2,383

 

 

 
2,386

Stock-based compensation
 

 

 
3,774

 

 

 
3,774

Other comprehensive loss
 

 

 

 
(16
)
 

 
(16
)
Balances, September 30, 2018
 
7,553

 
$
76

 
$
249,755

 
$
216

 
$
(138,446
)
 
$
111,601

See accompanying notes to condensed consolidated financial statements.

-4-




HESKA CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
 
 
Nine Months Ended
September 30,
 
 
2018
 
2017
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
 
Net income
 
$
2,383

 
$
10,525

Adjustments to reconcile net income to cash provided by operating activities:
 
 

 
 

Depreciation and amortization
 
3,473

 
3,586

Deferred income tax (benefit) expense
 
(1,997
)
 
762

Stock-based compensation
 
3,774

 
2,093

Other (income) expense
 
(2
)
 
7

Changes in operating assets and liabilities:
 
 

 
 

Accounts receivable
 
2,075

 
7,376

Inventories
 
3,935

 
(10,490
)
Due from related parties
 
1

 
78

Lease receivable, current
 
(708
)
 
(991
)
Other current assets
 
(778
)
 
(341
)
Accounts payable
 
(4,945
)
 
1,835

Due to related parties
 
(1,422
)
 
1,145

Accrued liabilities and other
 
6,102

 
(3,046
)
Lease receivable, non-current
 
(1,906
)
 
(3,985
)
Other non-current assets
 
(1,256
)
 
(620
)
Deferred revenue and other
 
(2,271
)
 
(1,656
)
Net cash provided by operating activities
 
6,458

 
6,278

CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
 
Purchase of minority interest
 

 
(13,757
)
Investments in unconsolidated affiliates
 
(8,089
)
 

Purchases of property and equipment
 
(1,061
)
 
(1,998
)
Proceeds from disposition of property and equipment
 
24

 
6

Net cash used in investing activities
 
(9,126
)
 
(15,749
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
 
Proceeds from issuance of common stock
 
3,627

 
2,287

Repurchase of common stock
 
(1,241
)
 
(860
)
Proceeds from line of credit borrowings
 
3,000

 
40,307

Repayments of line of credit borrowings
 
(3,000
)
 
(34,666
)
Distributions to non-controlling interest members
 
(126
)
 
(963
)
Repayments of other debt
 
(5
)
 
(78
)
Net cash provided by financing activities
 
2,255

 
6,027

EFFECT OF EXCHANGE RATE CHANGES ON CASH
 
(10
)
 
73

DECREASE IN CASH AND CASH EQUIVALENTS
 
(423
)
 
(3,371
)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD
 
9,659

 
10,794

CASH AND CASH EQUIVALENTS, END OF PERIOD
 
$
9,236

 
$
7,423

 
 
 
 
 
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
 
 
 
 
Non-cash transfers of equipment between inventory and property and equipment, net
 
$
1,019

 
$
824

See accompanying notes to condensed consolidated financial statements.

-5-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS



1.    OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Heska Corporation and its wholly-owned subsidiaries ("Heska", the "Company", "we" or "our") sell veterinary and animal health diagnostic and specialty products. Our offerings include Point of Care diagnostic laboratory instruments and consumables, digital imaging diagnostic products, software and services, vaccines, local and cloud-based data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. Our core focus is on supporting veterinarians in the canine and feline healthcare space.
Basis of Presentation and Consolidation
In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting of normal, recurring adjustments, necessary to present fairly the financial position of the Company as of September 30, 2018 and December 31, 2017, the results of our operations and statements of stockholders' equity for the three and nine months ended September 30, 2018 and 2017, as well as cash flows for the nine months ended September 30, 2018 and 2017.
The unaudited Condensed Consolidated Financial Statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. Our unaudited Condensed Consolidated Financial Statements include our accounts and the accounts of our wholly-owned subsidiaries since their respective dates of acquisitions. All intercompany accounts and transactions have been eliminated in consolidation. Where our ownership of a subsidiary was less than 100%, the non-controlling interest is reported on our Condensed Consolidated Balance Sheets. The non-controlling interest in our consolidated net income is reported as "Net loss attributable to non-controlling interest" on our Condensed Consolidated Statements of Income. These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and Notes thereto contained in our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2017 and other financial information filed with the SEC.
Reclassification
To maintain consistency and comparability, certain amounts in the financial statements have been reclassified to conform to current year presentation.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates are required when establishing the allowance for doubtful accounts and the net realizable value of inventory; determining future costs associated with warranties provided; determining the period over which our obligations are fulfilled under agreements to license product rights and/or technology rights; evaluating long-lived and intangible assets and investments for impairment; estimating the useful lives of instruments under leasing arrangements; determining the allocation of purchase price under purchase accounting; estimating the expense associated with the granting of stock options; and determining the need for, and the amount of a valuation allowance on deferred tax assets.

-6-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Critical Accounting Policies
Our accounting policies are described in our audited Consolidated Financial Statements and Notes thereto contained in our Annual Report on Form 10-K/A for the year ended December 31, 2017, and other than the recently adopted accounting pronouncements and Investment in Unconsolidated Affiliates policy discussed below, have not changed significantly since such filing.
Investments in Unconsolidated Affiliates
Investments in unconsolidated affiliates are measured and recorded as either non-marketable equity securities or equity method investments. Non-marketable equity securities are equity securities without readily determinable fair value that are measured and recorded using a measurement alternative which measures the securities at cost minus impairment, if any, plus or minus changes from qualifying observable price changes. Equity method investments are equity securities in investees we do not control but over which we have the ability to exercise significant influence. When the equity method of accounting is determined to be appropriate, the initial measurement of the investment includes the cost of the investment and all direct transaction costs incurred to acquire the investment. Equity method investments are measured at cost minus impairment, if any, plus or minus our share of equity method investee income or loss, which will be recorded as a separate line on the income statement. Both types of investments will be evaluated for impairment if a triggering event occurs.
Adoption of New Accounting Pronouncements

In August 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which became effective for us beginning January 1, 2018. The new standard made eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. Adoption of this standard did not have a material impact on our financial statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers and has subsequently issued several supplemental and/or clarifying Accounting Standards Updates or ASUs (collectively “ASC 606”). ASC 606 prescribes a single common revenue standard that replaces most existing GAAP revenue recognition guidance. ASC 606 outlines a five-step model, under which Heska will recognize revenue as performance obligations within customer contracts are satisfied. ASC 606 is intended to provide more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability. Along with the issuance of ASC 606, additional cost guidance was issued and codified under ASC 340-40 that outlines the requirement for capitalizing incremental costs of obtaining a contract and costs to fulfill a contract that meet certain capitalization criteria.

On January 1, 2018, we adopted ASC 606 using the modified retrospective method for all customer contracts not yet completed as of the adoption date. Results for reporting periods beginning January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and continue to be reported in accordance with the Company’s historic accounting under Topic 605, Revenue Recognition.

We recorded an increase to beginning retained earnings of $2.6 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606. The impact to beginning retained earnings was primarily driven by the capitalization of certain costs to obtain our customer contracts, which were primarily sales-related commissions. The adoption of ASC 606 did not have a significant impact on our Condensed Consolidated Financial Statements as of and for the three and nine months ended September 30, 2018. As a result,

-7-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


comparisons of revenues and operating profit performance between periods are not affected by the adoption of this ASU. 

We generate our Core Companion Animal (“CCA”) segment revenue through the sale of products, either by outright purchase by our customers or through a subscription agreement whereby our customers receive instruments and pay us a monthly fee for the usage of the instrument as well as the consumables needed to conduct testing. Outright sales to customers are the majority of both Point of Care imaging diagnostic transactions and the sale of pharmaceuticals and vaccines, while subscription placement is the majority of Point of Care diagnostic laboratory transactions.

For outright sales of products, revenue is recognized when control of the promised product or service is transferred to our customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606. For instruments, consumables, and most software licenses sold by the Company, control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment, legal title must have passed to the customer, the customer must have the significant risks and rewards of ownership, and where acceptance is not a formality, the customer must have accepted the product or service. Heska’s principal terms of sale are FOB Shipping Point, or equivalent, and, as such, we primarily transfer control and record revenue for product sales upon shipment. If a performance obligation to the customer with respect to a sales transaction remains unfulfilled following shipment (typically owed installation or acceptance by the customer), revenue recognition for that performance obligation is deferred until such commitments have been fulfilled. We do not generally allow return of products or instruments. For extended warranty and service plans, control transfers to the customer over the term of the arrangement. Revenue for extended warranties and service is recognized based upon the period of time elapsed under the arrangement.

Our revenue under subscription agreements relate to operating-type lease (“OTL”) arrangements or sales-type lease (“STL”) arrangements. A STL would result in earlier recognition of instrument revenue as compared to an OTL, which is generally upon installation of the instruments. The cost of the customer-leased instruments is removed from inventory and recognized in the Condensed Consolidated Statements of Income. Determination of an OTL or STL is primarily based on the length of the contract as compared to the estimated useful life of the instrument, among other factors. Leases are outside of the scope of ASC 606 and are therefore accounted for in accordance with ASC 840, Leases. Instrument lease revenue for OTL agreements is recognized on a straight-line basis over the life of the lease, and the costs of customer-leased instruments are recorded within property and equipment in the accompanying Condensed Consolidated Balance Sheets and depreciated over the instrument’s estimated useful life. The depreciation expense is reflected in cost of revenue in the accompanying Condensed Consolidated Statements of Income. The OTLs and STLs are not cancellable until after an initial term. Under either type of lease, we often charge a subscription fee and provide a minimum supply credit. OTLs may include a minimum utilization rather than a minimum supply credit.
    
For contracts with multiple performance obligations, the Company allocates the contracts' transaction price for each performance obligation on a relative standalone selling price basis using our best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate the standalone selling price is the price observed in standalone sales to customers. However, when prices in standalone sales are not available, we may use a cost-plus margin approach. Allocation of the transaction price is determined at the contracts' inception. The Company does not adjust the transaction price for the effects of a significant financing component when the period between the transfer of the promised good or service to the customer and payment for that good or service by the customer is expected to be one

-8-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


year or less. This allocation approach also applies to contracts for which a portion of the contract relates to a lease component.

We generate revenue within our Other Vaccines, Pharmaceuticals, and Products (“OVP”) segment through contract manufacturing agreements with customers. The timing of revenue recognition of our customer contracts are generally recognized upon shipment or acceptance by our customer, under the same guidelines noted above for other outright product sales. Heska assessed the over-time criteria within ASC 606 and concluded that because products within this segment have no alternative use to Heska, as Heska is contractually prohibited to redirect the product to other customers, Heska does not have right to payment for performance to date. Therefore, point in time revenue recognition has been determined to be appropriate.

Revenue generated from licensing arrangements is recognized based on the underlying term of the contract.

Refer to Note 2 for additional disclosures required by ASC 606.

Accounting Pronouncements Not Yet Adopted
    
In June 2018, the FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with accounting for employee share-based compensation. ASU 2018-07 is effective for annual periods beginning after December 15, 2018 and interim periods within those annual periods, with early adoption permitted but no earlier than an entity’s adoption date of Topic 606. We will adopt the provisions of this ASU in the first quarter of 2019. Adoption of the new standard is not expected to have a material impact on our Consolidated Financial Statements.

In February 2018, the FASB issued ASU 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The ASU permits companies to elect a reclassification of the disproportionate tax effects in accumulated other comprehensive income ("AOCI") caused by the Tax Cuts and Jobs Act of 2017 to retained earnings. The ASU also requires additional disclosures. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with early adoption permitted. We will adopt the provisions of this ASU in the first quarter of 2019. Adoption of the new standard is not expected to have a material impact on our Consolidated Financial Statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), which require that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the increases or decreases of expected credit losses that have taken place during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The amendments in this update are effective for fiscal years beginning after December 15, 2019 and interim periods within those annual periods. Early adoption for fiscal year beginning after December 15, 2018 is permitted. We will adopt the provisions of this ASU in the first quarter of 2020. We are currently evaluating the effect of this update on our consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes ASC 840, Leases. This update requires lessees to recognize a lease liability and a lease asset for all leases, including operating

-9-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


leases, with a term greater than 12 months on its balance sheet. The update also expands the required quantitative and qualitative disclosures surrounding leases. The accounting for lessors does not fundamentally change except for changes to conform and align guidance to the lessee guidance as well as to the new revenue recognition guidance in ASU 2014-09. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases and ASU 2018-11, Leases, Targeted Improvements, which provide additional clarification and implementation guidance on certain aspects of ASU 2016-02 and have the same effective date and transition requirements. Specifically, ASU 2018-10 provides certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02, and ASU 2018-11 and creates an additional transition method option allowing entities to record a cumulative effect adjustment to the opening retained earnings balance in the year of adoption. ASU 2018-11 also allows lessors to not separate nonlease components from the associated lease component if certain conditions are met. These updates will be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. We are currently evaluating the effect of this update on our consolidated financial statements.
In July 2018, the FASB issued ASU No. 2018-09, Codification Improvements. This update provides amendments to a wide variety of topics in the FASB's Accounting Standards Codification, which applies to all reporting entities within the scope of the affected accounting guidance. The transition and effective date guidance are based on the facts and circumstances of each amendment. Some of the amendments within ASU 2018-09 do not require transition guidance and were effective upon issuance. However, many amendments do have transition guidance with effective dates for annual periods beginning after December 15, 2018. We are currently evaluating the potential impact of adopting the applicable guidance on our consolidated financial statements.


2.     REVENUE

We separate our goods and services among:

Point of Care laboratory products including instruments, consumables, and services;
Point of Care imaging products including instruments, software, and services;
Single use pharmaceuticals, vaccines, and diagnostic tests primarily related to companion animals; and
Other vaccines and pharmaceuticals.

-10-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Revenue from our CCA segment consists of Point of Care laboratory products, including instruments and consumables, Point of Care imaging products, and single use diagnostic and other tests, pharmaceuticals and biologicals. Point of Care laboratory products are generally sold under a long-term subscription agreement with the instrument portion of the sale accounted for under Topic 840, Leases, as either an OTL or STL. For STL, we apply the provisions of ASC 606 to determine the point in time when control is transferred to the customer, generally when installation of the instrument occurs. Related profit and derecognition of the asset from the Company's balance sheet follows prescribed guidance under ASC 840. Revenue recognized under this topic was approximately $1.2 million and $4.6 million in the three and nine months ended September 30, 2018, respectively. For the three and nine months ended September 30, 2018, we recognized approximately $1.4 million and $3.5 million, respectively, of instrument sales related to the outright sale of instruments to customers, which also included shipping and preparation fees. Consumables are critical to the use of the Point of Care laboratory instruments and are used one-time, requiring frequent replacement in the customer's operating cycle. Revenue recorded related to sales of consumables was $11.6 million and $33.9 million in the three and nine months ended September 30, 2018, respectively. Other services, such as extended service plans and repairs, resulted in approximately $0.4 million and $1.2 million of revenue in the three and nine months ended September 30, 2018, respectively.
Point of Care imaging instruments and software are generally sold outright to customers and recognized upon shipment, which is generally the point in time when control transfers to customers. Revenue of approximately $4.4 million and $13.2 million was recognized in the three and nine months ended September 30, 2018, respectively. Rental agreements, generally accounted for as OTLs under Topic 840, Leases, resulted in approximately $0.3 million and $0.9 million of rental revenue in the three and nine months ended September 30, 2018, respectively. Service revenue, including extended warranty revenue, of approximately $0.6 million and $1.7 million was recognized in the three and nine months ended September 30, 2018, respectively.
Revenue from single use diagnostic and other tests, pharmaceuticals and biologicals as well as research and development, licensing and royalty revenue, represented approximately $7.3 million of our revenue for the three months ended September 30, 2018, and $21.6 million of our revenue for the nine months ended September 30, 2018. Of those amounts, approximately $0.1 million and $0.3 million related to license and royalty income for the three and nine months ended September 30, 2018, respectively.

Revenue from our OVP segment consists of revenue generated from contract manufacturing agreements and from other license and research and development. Revenue from contract manufacturing contracts and from other license and research and development was $3.6 million and $0.2 million, respectively, in the three months ended September 30, 2018, and $12.2 million and $0.5 million, respectively, in the nine months ended September 30, 2018.

Remaining Performance Obligations

Remaining performance obligations related to ASC 606 represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year which are fully or partially unsatisfied at the end of the period. Remaining performance obligations include noncancelable purchase orders, the non-lease portion of minimum purchase commitments under long-term supply arrangements, extended warranty, service and other long-term contracts. Remaining performance obligations do not include revenue from contracts with customers with an original term of one year or less, revenue from long-term supply arrangements with no minimum purchase requirements, revenue expected from purchases made in excess of the minimum purchase requirements, or revenue from instruments leased to customers. While the remaining performance obligation disclosure is similar in concept to backlog, the definition of remaining performance obligations excludes leases and contracts that provide the customer with the right to cancel or

-11-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


terminate for convenience with no substantial penalty, even if historical experience indicates the likelihood of cancellation or termination is remote. Additionally, the Company has elected to exclude contracts with customers with an original term of one year or less from remaining performance obligations while these contracts are included within backlog.

As of September 30, 2018, the aggregate amount of the transaction price allocated to remaining minimum performance obligations was approximately $81.5 million. As of September 30, 2018, the Company expects to recognize revenue as follows (in thousands):

Year Ending December 31,
Revenue

2018 (remaining)
$
5,980

2019
21,682

2020
18,084

2021
14,040

2022
10,832

Thereafter
10,843

 
$
81,461


Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue, and customer deposits and billings in excess of revenue recognized (contract liabilities) on the Condensed Consolidated Balance Sheets. In addition, the Company defers certain costs incurred to obtain contracts (contract costs).

Contract Assets

Most of the Company’s long-term contracts are billed as product is shipped. However, during the three and nine months ended September 30, 2018, the Company recognized $1.8 million of revenue prior to invoicing, which is included in Accounts Receivable, net, on the Condensed Consolidated Balance Sheets. Invoicing is expected prior to December 31, 2018.

Contract Liabilities

The Company receives cash payments from customers for licensing fees or other arrangements that extend for a specified term. These contract liabilities are classified as either current or long-term in the Condensed Consolidated Balance Sheets based on the timing of when the Company expects to recognize revenue. As of September 30, 2018 and December 31, 2017, contract liabilities were $9.9 million and $12.3 million, respectively, and are included within the current portion of "Deferred revenue" and the non-current portion of "Deferred revenue, net of current portion, and other" in the accompanying Condensed Consolidated Balance Sheets. The decrease in the contract liability balance during the nine month period ended September 30, 2018 is $3.4 million of revenue recognized during the period, offset by $1.0 million of additional deferred sales in 2018.

Contract Costs

The Company capitalizes certain direct incremental costs incurred to obtain customer contracts, typically sales-related commissions, where the recognition period for the related revenue is greater than one year.

-12-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Contract costs are classified as current or non-current "Contract acquisition costs" in the Condensed Consolidated Balance Sheets based on the timing of when the Company expects to recognize the expense and are generally amortized into earnings with a certain percentage recognized immediately based upon placement of the instrument with the remainder recognized on a straight-line basis (which is consistent with the transfer of control for the related goods or services) over the term of the contract. Management assesses these costs for impairment at least quarterly on a contract by contract basis and as “triggering” events occur that indicate it is more likely than not that an impairment exists. The balance of contract costs as of September 30, 2018 and at the date of adoption was $2.5 million and $2.4 million, respectively. Amortization expense for the nine month period ended September 30, 2018 was $0.7 million, offset by $0.8 million of additional contract costs capitalized in 2018. The costs to obtain a contract where the amortization period for the related asset is one year or less are expensed as incurred and recorded within selling and marketing expenses and general and administrative expenses in the accompanying Condensed Consolidated Statements of Income.

Contract liabilities are reported on the accompanying Condensed Consolidated Balance Sheets on a contract-by-contract basis whereas contract costs are calculated and reported on a portfolio basis.

3.    ACQUISITIONS AND RELATED PARTY ITEMS
Cuattro Veterinary, LLC
On May 31, 2016, the Company closed a transaction (the "Merger") to acquire Cuattro Veterinary, LLC ("Cuattro International"), which was owned by Kevin S. Wilson, among other members (the "Members"). The Company recorded assets acquired and liabilities assumed at their estimated fair values. Intangible assets were valued based on a report from an independent third party. The goodwill associated with the acquisition is the result of expected synergies and expansion of the technology into additional markets.
Cuattro International is a provider to international markets of digital radiography technologies for veterinarians. As a leading provider of advanced veterinary diagnostic and specialty products, we made the acquisition in an effort to combine Cuattro International's international reach with our domestic success in the imaging and laboratory markets in the United States. International markets represent a significant portion of worldwide veterinary revenues.
As of the closing date of the Merger, Cuattro International was renamed Heska Imaging International, LLC, ("International Imaging") and the Company's interest in both International Imaging and Heska Imaging US, LLC ("US Imaging") was transferred to the Company's wholly-owned subsidiary, Heska Imaging Global, LLC ("Global Imaging").
Mr. Wilson is a founder of Cuattro International, Cuattro, LLC, Cuattro Software, LLC and Cuattro Medical, LLC. Mr. Wilson, Mrs. Wilson and trusts for the benefit of Mr. and Mrs. Wilson’s children and family own a 100% interest in Cuattro, LLC and a majority interest in Cuattro Medical, LLC. Cuattro, LLC owns a 100% interest in Cuattro Software, LLC and prior to the Merger, owned a majority interest in Cuattro International.
Cuattro Veterinary USA, LLC
On February 24, 2013, the Company acquired a 54.6% interest in Cuattro Veterinary USA, LLC (the "Acquisition"), which was subsequently renamed Heska Imaging US, LLC ("US Imaging"). The remaining minority position (45.4%) in US Imaging was subject to purchase by Heska under performance-based puts and calls following the audit of our financial statements for the 2016 and 2017 fiscal years. With the required performance criteria met in fiscal year 2016, we considered notice given on March 3, 2017 that the put option was being exercised and on May 31, 2017, we delivered $13.8 million in cash to obtain the remaining minority interest position in US Imaging.

-13-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Prior to the purchase of the minority interest position (the "Imaging Minority"), Shawna M. Wilson, Clint Roth, DVM, Steven M. Asakowicz, Rodney A. Lippincott, Kevin S. Wilson and Cuattro, LLC owned approximately 29.75%, 8.39%, 4.09%, 3.07%, 0.05% and 0.05% of US Imaging, respectively. Kevin S. Wilson is the Chief Executive Officer and President of the Company and the spouse of Shawna M. Wilson. Steven M. Asakowicz and Rodney A Lippincott each serve as Executive Vice President, Companion Animal Health Sales for the Company. On April 3, 2017, and in accordance with the terms of its Operating Agreement, US Imaging distributed $2.1 million based on past operating performance, including $1.0 million to its minority interest members. As of December 31, 2017, US Imaging accrued an additional $0.3 million distribution, including $0.1 million to its minority interest members, all of which was paid in January 2018.
On June 1, 2017, the Company consolidated its assets and liabilities in the US Imaging and International Imaging companies into Global Imaging, which was re-named Heska Imaging, LLC ("Heska Imaging").
Related Party Activities
Cuattro, LLC charged Heska Imaging $3.1 million and $13.9 million during the nine months ended September 30, 2018 and 2017, respectively, primarily for digital imaging products, pursuant to an underlying supply contract that contains minimum purchase obligations, software and services as well as other operating expenses. The Company charged US Imaging $2.9 million during the five months ended May 31, 2017, prior to the purchase of the Imaging Minority on May 31, 2017, primarily related to sales expenses. The Company charged Cuattro, LLC approximately $2 thousand and $0.1 million during the nine months ended September 30, 2018, and 2017, respectively, for facility usage and other services.
The Company had receivables from Cuattro, LLC of approximately $0 and $1 thousand as of September 30, 2018 and December 31, 2017, respectively, which is included in "Due from – related parties" on the Company's Condensed Consolidated Balance Sheets. Heska Imaging owed Cuattro, LLC $0.3 million and $1.7 million as of September 30, 2018 and December 31, 2017, respectively, which is included in "Due to – related parties" on the Company's Condensed Consolidated Balance Sheets.


-14-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


4.    INVESTMENTS IN UNCONSOLIDATED AFFILIATES
The carrying values of investments in unconsolidated affiliates, categorized by type of investment, is as follows (in thousands):
 
September 30, 2018
Equity method investment
$
5,071

Non-marketable equity security investment
3,018

 
$
8,089

Equity Method Investment
On September 24, 2018, we invested $5.0 million in exchange for a 28.7% interest of a business as part of our product development strategy . The Company accounts for its investment using the equity method of accounting. Under the equity method, the carrying value of the investment is adjusted for the Company's proportionate share of the investee's reported earnings or losses with the corresponding share of earnings or losses reported as Equity in Earnings of Unconsolidated Affiliates, listed below Net (loss) income within the consolidated statement of operations. The Company intends to account for this equity method investment on the same basis as its financial reporting cycle. The investment was completed with only six days left in the reporting period, and thus the results from the investment were deemed to be not material to the three months ended September 30, 2018. Equity earnings from this investment is expected to be reported as a separate line in the Consolidated Statements of Income in future reporting periods.
Additionally, the Company also entered into a 15-year Manufacturing Supply Agreement, which grants the Company global exclusivity to specified products.
Non-Marketable Equity Security Investment

On August 8, 2018, the Company invested $3.0 million in MBio Diagnostics, Inc. ("MBio"), in exchange for preferred stock, representing a 6.9% interest in MBio. The Company’s investment in MBio is a non-marketable equity security, recorded using the measurement alternative of cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes.

As part of the agreement, the Company entered into a Supply and License Agreement with MBio, which provides that MBio produce and commercialize products that will enhance the Company's diagnostic portfolio. As part of this agreement, the Company made an upfront payment to MBio of $1.0 million related to a worldwide exclusive license agreement over a 20-year period, recorded in both short and long-term other assets. In addition, the agreement provides for an additional contingent payment from Heska to MBio of $10.0 million, relating to the successful achievement of sales milestones. This potential future milestone payment has not yet been accrued as it is not deemed by the Company to be probable at this time.

Both parties in this arrangement are active participants and are exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. The parties are actively working on developing and testing the product as well as funding the research and development. Heska classifies the amounts paid for MBio's research and development work within the CCA segment research and development operating expenses. Expense is recognized ratably when incurred and in accordance with the development plan.


-15-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


5.    INCOME TAXES

Our total income tax (benefit) expense and the effective tax rate for our income before income taxes were as follows (in thousands):
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
2018
 
2017
 
2018
 
2017
(Loss) income before income taxes
 
$
(3,545
)
 
$
3,784

 
$
442

 
$
11,312

Total income tax (benefit) expense
 
(1,875
)
 
701

 
(1,941
)
 
787

Effective tax rate
 
(52.9
)%
 
18.5
%
 
(439.1
)%
 
7.0
%
    
There were cash payments of $0 thousand and $30 thousand, respectively, for income taxes, net of refunds, for the three and nine months ended September 30, 2018, and there were $2 thousand and $146 thousand in cash payments for income taxes, net of refunds, for the three and nine months ended September 30, 2017. The Company’s effective tax rate decreased to a tax benefit of (52.9)% and (439.1)%, respectively, for the three and nine months ended September 30, 2018, compared to a tax expense of 18.5% and 7.0%, respectively, for the three and nine months ended September 30, 2017. The decrease in rates for both periods was primarily attributable to a decrease in net income and an increase in stock-based compensation excess tax benefits. The decrease in net income for both periods was primarily due to a one-time accrual of settlement and legal expenses for pending litigation (see Note 13). While the Company believes the settlement and legal expenses are more likely than not deductible for tax purposes, and has treated it as such, the Company continues to evaluate its preliminary conclusion.

The Company continues to analyze the different aspects of the Tax Cuts and Jobs Act that was enacted in December 2017. Specifically, we continue to analyze the provisional amounts estimated for the possible impact of the global intangible low-taxed income or GILTI tax, and the possible executive compensation limitations imposed by IRC Section 162(m) of the Internal Revenue Code of 1986, as amended.
6.    EARNINGS PER SHARE
Basic (loss) earnings per share ("EPS") is computed by dividing net (loss) income attributable to the Company by the weighted-average number of common shares outstanding during the period. The computation of diluted EPS is similar to the computation of basic EPS except that the numerator is increased to exclude charges that would not have been incurred, and the denominator is increased to include the number of additional common shares that would have been outstanding (using the if-converted and treasury stock methods), if securities containing potentially dilutive common shares (stock options and restricted stock units but excluding options to purchase fractional shares resulting from the Company's December 2010 1-for-10 reverse stock split) had been converted to common shares, and if such assumed conversion is dilutive. All common stock equivalent securities were anti-dilutive for the three months ended September 30, 2018, because the Company reported a net loss for that period.

-16-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


The following is a reconciliation of the weighted-average shares outstanding used in the calculation of basic and diluted (loss) earnings per share for the three and nine months ended September 30, 2018 and 2017 (in thousands, except per share data):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net (loss) income attributable to Heska
$
(1,670
)
 
$
3,083

 
$
2,383

 
$
11,023

 
 
 
 
 
 
 
 
Basic weighted-average common shares outstanding
7,289

 
7,139

 
7,194

 
6,985

Assumed exercise of dilutive stock options and restricted shares

 
529

 
626
 
595

Diluted weighted-average common shares outstanding
7,289

 
7,668

 
7,820

 
7,580

 
 
 
 
 
 
 
 
Basic (loss) earnings per share attributable to Heska
$
(0.23
)
 
$
0.43

 
$
0.33

 
$
1.58

Diluted (loss) earnings per share attributable to Heska
$
(0.23
)
 
$
0.40

 
$
0.30

 
$
1.45

The following stock options and restricted shares were excluded from the computation of diluted (loss) earnings per share because they would have been anti-dilutive (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Stock options
675

 
27

 
190

 
132

7.    GOODWILL AND OTHER INTANGIBLES

The following summarizes the change in goodwill during the nine months ended September 30, 2018 (in thousands):
Carrying amount, December 31, 2017
$
26,687

Foreign currency adjustments
(5
)
Carrying amount, September 30, 2018
$
26,682


Other intangibles consisted of the following (in thousands):
 
September 30,
 
December 31,
 
2018
 
2017
Gross carrying amount
$
3,309

 
$
3,309

Accumulated amortization
(1,642
)
 
(1,351
)
Net carrying amount
$
1,667

 
$
1,958


Amortization expense relating to other intangibles was as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Amortization expense
$
97

 
$
97

 
$
291

 
$
291



-17-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Estimated amortization expense related to intangibles for each of the five years from 2018 (remaining) through 2022 and thereafter is as follows (in thousands):
Year Ending December 31,
 
2018 (remaining)
$
97

2019
388

2020
388

2021
384

2022
378

Thereafter
32

 
$
1,667

8.    PROPERTY AND EQUIPMENT
Property and equipment, net, consisted of the following (in thousands):
 
September 30,
 
December 31,
 
2018
 
2017
Land
$
377

 
$
377

Building
2,978

 
2,868

Machinery and equipment
39,683

 
38,432

Leasehold and building improvements
9,947

 
8,156

Construction in progress
1,179

 
3,531

 
54,164

 
53,364

Less accumulated depreciation
(37,880
)
 
(36,033
)
Total property and equipment, net
$
16,284

 
$
17,331

Depreciation expense was $1.0 million and $1.1 million for the three months ended September 30, 2018 and 2017, respectively. Depreciation expense was $3.2 million and $3.3 million for the nine months ended September 30, 2018 and 2017, respectively.
The Company has subscription agreements whereby its instruments in inventory may be placed at a customer's location on a rental basis. The cost of these instruments is transferred to machinery and equipment and depreciated, typically over a five-to-seven year period depending on the circumstance under which the instrument is placed with the customer. Our cost of instruments under operating leases as of September 30, 2018 and December 31, 2017, was $10.9 million and $10.8 million, respectively, before accumulated depreciation of $5.9 million and $5.0 million, respectively, and the net book value was $5.0 million and $5.7 million, respectively.

-18-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


9.    INVENTORIES, NET

Inventories, net, consisted of the following (in thousands):
 
 
September 30,
 
December 31,
 
 
2018
 
2017
Raw materials
 
$
16,346

 
$
18,465

Work in process
 
4,154

 
4,296

Finished goods
 
8,858

 
11,465

Allowance for excess or obsolete inventory
 
(1,719
)
 
(1,630
)
Total inventory, net
 
$
27,639

 
$
32,596


Inventories are stated at lower of cost (first-in, first-out) or net realizable value.
10.    ACCRUED LIABILITIES
Accrued liabilities consisted of the following (in thousands):
 
September 30,
2018
 
December 31,
2017
Accrued settlement (see Note 13)
$
6,750

 
$

Accrued purchases
1,008

 
695

Accrued payroll and employee benefits
758

 
1,209

Accrued property taxes
488

 
661

Other
1,514

 
1,852

Total accrued liabilities
$
10,518

 
$
4,417

Other accrued liabilities consists of items that are individually less than 5% of total current liabilities.
11.    CAPITAL STOCK
Stock Option Plans
The fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions for options granted in the three and nine months ended September 30, 2018 and 2017.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Risk-free interest rate
2.80%
 
1.83%
 
2.66%
 
1.75%
Expected lives
4.9 years
 
4.9 years
 
4.9 years
 
4.9 years
Expected volatility
40%
 
39%
 
40%
 
41%
Expected dividend yield
0%
 
0%
 
0%
 
0%

-19-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


A summary of our stock option plans is as follows:
 
Nine Months Ended September 30,
 
Year Ended
December 31,
 
2018
 
2017
 
 
 
 
Options
 
Weighted Average Exercise Price
 
 
 
 
Options
 
Weighted Average Exercise Price
Outstanding at beginning of period
630,847

 
$
29.312

 
829,617

 
$
23.203

Granted at market
152,200

 
$
75.010

 
27,050

 
$
99.087

Canceled
(19,708
)
 
$
53.109

 
(18,331
)
 
$
57.197

Exercised
(98,594
)
 
$
30.639

 
(207,489
)
 
$
11.520

Outstanding at end of period
664,745

 
$
38.873

 
630,847

 
$
29.312

Exercisable at end of period
414,018

 
$
19.378

 
456,802

 
$
18.316

The total estimated fair value of stock options granted during the nine months ended September 30, 2018 and 2017 was computed to be approximately $4.4 million and $1.0 million, respectively. The amounts are amortized ratably over the vesting periods of the options. The weighted average estimated fair value of options granted during the nine months ended September 30, 2018 and 2017 was computed to be approximately $28.74 and $37.41, respectively. The total intrinsic value of options exercised during the nine months ended September 30, 2018 and 2017 was $6.6 million and $16.5 million, respectively. The cash proceeds from options exercised during the nine months ended September 30, 2018 and 2017 was $3.0 million and $1.8 million, respectively.
The following table summarizes information about stock options outstanding and exercisable at September 30, 2018:
 
 
Options Outstanding
 
Options Exercisable
Exercise Prices
 
Number of
Options
Outstanding
at
September 30,
2018
 
Weighted
Average
Remaining
Contractual
Life in Years
 
Weighted
Average
Exercise
Price
 
Number of
Options
Exercisable
at
September 30,
2018
 
Weighted
Average
Exercise
Price
$  4.40 - $  6.90
 
92,535

 
1.89
 
$
5.378

 
92,535

 
$
5.378

$  6.91 - $  8.55
 
148,004

 
4.85
 
$
7.764

 
148,004

 
$
7.764

$  8.56 - $ 39.56
 
112,428

 
6.33
 
$
23.164

 
105,533

 
$
23.242

$ 39.57 - $ 69.77
 
194,733

 
8.70
 
$
59.852

 
37,735

 
$
39.898

$ 69.78 - $ 108.25
 
117,045

 
8.62
 
$
84.874

 
30,211

 
$
80.036

$  4.40 - $ 108.25
 
664,745

 
6.48
 
$
38.873

 
414,018

 
$
19.378

As of September 30, 2018, there was approximately $5.9 million in total unrecognized compensation cost related to outstanding stock options. That cost is expected to be recognized over a weighted average period of 1.79 years, with all cost to be recognized by the end of July 2022, assuming all options vest according to the vesting schedules in place at September 30, 2018. As of September 30, 2018, the aggregate intrinsic value of outstanding options was approximately $49.5 million and the aggregate intrinsic value of exercisable options was approximately $38.9 million.

-20-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Employee Stock Purchase Plan (the "ESPP")

For the three months ended September 30, 2018 and 2017, we issued 1,942 and 2,515 shares under the ESPP, respectively. For the nine months ended September 30, 2018 and 2017, we issued 7,396 and 8,058 shares under the ESPP, respectively.
For the three and nine months ended September 30, 2018 and 2017, we estimated the fair values of stock purchase rights granted under the ESPP using the Black-Scholes pricing model. The weighted average assumptions used for the periods presented were as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Risk-free interest rate
2.04%
 
0.76%
 
1.39%
 
0.70%
Expected lives
1.1 years
 
1.2 years
 
1.2 years
 
1.2 years
Expected volatility
42%
 
45%
 
43%
 
45%
Expected dividend yield
0%
 
0%
 
0%
 
0%
For the three months ended September 30, 2018 and 2017, the weighted-average fair value of the purchase rights granted was $23.44 and $16.49 per share, respectively. For the nine months ended September 30, 2018 and 2017, the weighted-average fair value of the purchase rights granted was $17.85 and $15.90 per share, respectively.
Restricted Stock Issuance
On March 26, 2014, we issued 110,000 shares to Mr. Wilson pursuant to an employment agreement between Mr. Wilson and the Company effective as of March 26, 2014 (the "Wilson Employment Agreement"). The shares were issued in four equal tranches and subject to time-based vesting and other provisions outlined in the Wilson Employment Agreement. On March 26, 2017, the final of these four equal tranches of 27,500 shares vested.
On March 17, 2015, the Company issued 52,956 unvested shares to certain Executive Officers related to performance-based restricted stock grants (the "Performance Grants"). The Performance Grants have met the underlying performance condition based on the Company's 2015 financial performance and vested on March 17, 2018, subject to other vesting provisions in the underlying restricted stock grant agreement. Of the shares issued, 52,956 vested, 0 were forfeited, and 14,334 were withheld for tax.
On March 2, 2016, the Company issued 15,000 unvested shares to certain Executive Officers related to performance-based restricted stock grants as part of the Company’s 2016 Management Incentive Plan (the "2016 MIP Grants"). Of the shares issued, 14,629 vested, 371 were forfeited, and 4,133 were withheld for tax. The 2016 MIP Grants vested during the three months ended March 31, 2017.
On May 1, 2017, the Company issued 2,720 unvested shares to the Company's non-employee directors. These grants were to vest (the "Vesting Time") in full on the latter of (i) the one year anniversary of the date of grant and (ii) the Company’s Annual Meeting of Stockholders for the year following the year of grant for the award (the "Vesting Meeting"), subject to (i) the non-employee director's continued service to the Company through the Vesting Time, unless the non-employee director’s current term expires at the Vesting Meeting in which case vesting is subject to the non-employee director’s service to the Vesting Meeting and (ii) the non-employee director not engaging in “competition”, as defined in a restricted stock grant agreement executed by the non-employee director, to the Vesting Time. Of these shares, all vested on May 3, 2018.

-21-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


On May 31, 2017, the Company issued 23,700 unvested performance-based restricted shares to certain key employees. The vesting of these shares is subject to the achievement of certain Company performance and market conditions that must be met on or before May 30, 2024.
On June 15, 2017, the Company issued 6,594 unvested restricted shares to certain Executive Officers related to performance-based restricted stock grants as part of the Company’s 2017 Management Incentive Plan. As of December 31, 2017, all shares were forfeited and no compensation expense was recorded for the year ended December 31, 2017.

On March 7, 2018, the Company issued 128,500 unvested shares of performance-based restricted common stock and stock options with 130,000 underlying shares of common stock under the 1997 Plan, including 118,500 shares of performance-based restricted common stock and stock options with 120,000 underlying shares of common stock granted to Company Executive Officers. The vesting of the performance-based restricted shares is subject to the achievement of certain Company performance and market conditions and, in some instances, a service period requirement. The shares are to be forfeited if the applicable performance or market condition is not met by the date in each fiscal year that the Company's independent registered public accountants issue their financial report on the Company's prior fiscal year financial statements in 2025 or March 31, 2025, respectively, with the exception of 27,539 shares of restricted common stock with vesting tied to the Company's stock outperforming the S&P 500 Index over a two or four year time period, which will be forfeited if not achieved at the specified time. The stock options are to vest annually in three approximately equal tranches and immediately upon a change in control. 

On May 3, 2018, the Company issued 4,230 unvested shares to the Company's non-employee directors. These grants were to vest (the "Vesting Time") in full on the latter of (i) the one year anniversary of the date of grant or (ii) the Company’s Annual Meeting of Stockholders for the year following the year of grant for the award (the "Vesting Meeting"), subject to (a) the non-employee director's continued service to the Company through the Vesting Time, unless the non-employee director’s current term expires at the Vesting Meeting, in which case vesting is subject to the non-employee director’s service to the Vesting Meeting, and (b) the non-employee director not engaging in “competition”, as defined in a restricted stock grant agreement executed by the non-employee director, until the Vesting Time. 

On May 3, 2018, the Company issued 33,000 unvested shares of performance-based restricted common stock under the 1997 Plan to the Company's Chief Executive Officer, Kevin Wilson, which was contingent on stockholder approval to approve an increase of 250,000 common shares available for awards under the 1997 Stock Incentive Plan, which was approved consistent with the grant date. The vesting of the performance-based restricted shares is subject to the achievement of certain Company performance conditions and a service period requirement. The shares are to be forfeited if the applicable performance or market condition is not met by the date in each fiscal year that the Company's independent registered public accountants issue their financial report on the Company's prior fiscal year financial statements in 2025 or March 31, 2025.

On July 25, 2018, the Company issued 25,000 unvested shares of performance-based restricted common stock and stock options with 20,000 underlying shares of common stock under the 1997 Plan to one of the Company's Executive Officers. The vesting of the performance-based restricted shares is subject to the achievement of certain Company performance and market conditions and, in some instances, a service period requirement. The shares are to be forfeited if the applicable performance or market condition is not met by the date in each fiscal year that the Company's independent registered public accountants issue their financial report on the Company's prior fiscal year financial statements in 2025 or March 31, 2025, respectively, with the exception of 3,334 shares of restricted common stock with vesting tied to the Company's stock outperforming the S&P 500 Index over a two or four year time period, which will be forfeited if not achieved

-22-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


at the specified time. The stock options are to vest annually in three approximately equal tranches and immediately upon a change in control. 

As of September 30, 2018, there was approximately $3.7 million of total unrecognized compensation cost related to restricted stock with probable achievement of performance and market conditions. The Company expects to recognize this expense over a weighted average period of 1.8 years.
Restrictions on the transfer of Company stock
The Company's Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), places restrictions (the "Transfer Restrictions") on the transfer of the Company's stock that could adversely affect the Company's ability to utilize its domestic federal net operating loss position. In particular, the Transfer Restrictions prevent the transfer of shares without the approval of the Company's Board of Directors if, as a consequence of such transfer, an individual, entity or groups of individuals or entities would become a 5-percent holder under Section 382 of the Internal Revenue Code of 1986, as amended, and the related Treasury regulations, and also prevents any existing 5-percent holder from increasing his or her ownership position in the Company without the approval of the Company's Board of Directors. Any transfer of shares in violation of the Transfer Restrictions (a "Transfer Violation") shall be void ab initio under the Certificate of Incorporation, and the Company's Board of Directors has procedures under the Certificate of Incorporation to remedy a Transfer Violation, including requiring the shares causing such Transfer Violation to be sold and any profit resulting from such sale to be transferred to a charitable entity chosen by the Company's Board of Directors in specified circumstances.
12.    ACCUMULATED OTHER COMPREHENSIVE INCOME
Accumulated other comprehensive income consisted of the following (in thousands):
 
Minimum Pension Liability
 
Foreign Currency Translation
 
Total Accumulated Other Comprehensive Income
Balances at December 31, 2017
$
(489
)
 
$
721

 
$
232

Current period other comprehensive loss

 
(16
)
 
(16
)
Balances at September 30, 2018
$
(489
)
 
$
705

 
$
216

13.    COMMITMENTS AND CONTINGENCIES
Royalty Agreements
The Company holds certain rights to market and manufacture products developed or created under certain research, development, and licensing agreements with various entities. In connection with such agreements, the Company has agreed to pay the entities royalties on net product sales. In each of the three months ended September 30, 2018 and 2017, royalties of $0.1 million became payable under these agreements. In each of the nine months ended September 30, 2018 and 2017, royalties of $0.3 million became payable under these agreements.
Warranties

The Company's current terms and conditions of sale include a limited warranty that its products and services will conform to published specifications at the time of shipment and a more extensive warranty related to

-23-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


certain of its products. The Company also sells a renewal warranty for certain of its products. The typical remedy for breach of warranty is to correct or replace any defective product, and if not possible or practical, the Company will accept the return of the defective product and refund the amount paid. Historically, the Company has incurred minimal warranty costs. The Company's warranty reserve was $0.2 million at both September 30, 2018 and December 31, 2017.

Litigation
From time to time, the Company may be involved in litigation relating to claims arising out of its operations. The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred, and the amount can be reasonably estimated.

As previously disclosed in the Company's Current Report on Form 8-K filed with the SEC on October 16, 2018, which is incorporated herein by reference, on October 10, 2018, following mediation before the Hon. James Holderman (ret.) of the United States District Court for the Northern District of Illinois (the "Court"), the Company entered into an agreement in principle to settle the complaint that was filed against it in the Court as a putative class action on March 12, 2015, by Shaun Fauley alleging the Company's transmittal of unauthorized faxes in violation of the federal Telephone Consumer Protection Act of 1991, as amended by the Junk Fax Prevention Act of 2005 (the “TCPA”). The settlement remains subject to the execution of a written settlement agreement among the parties and the approval of such settlement by the Court. If approved, the Company would receive a full release from the settlement class, other than from those class members who timely elect to opt out of the settlement, concerning the claims asserted, or that could have been asserted, with respect to the conduct alleged in the complaint, and would make available a total of $6.75 million to pay class members, an incentive payment to the class representative, notice and administration costs in connection with the settlement, and attorneys' fees and expenses to legal counsel to the class. The Company has recorded an estimated loss provision of approximately $6.9 million in the third quarter of 2018 in connection with the settlement agreement and expenses associated with the matter, which is included in general and administrative expenses in the unaudited Condensed Consolidated Statements of Income, and included in accrued liabilities on the unaudited Condensed Consolidated Balance Sheet.

The Company has denied and continues to deny the allegations of Shaun Fauley and that it violated the TCPA. Nothing in this report or any settlement agreement shall be deemed to assign or reflect any admission of fault, wrongdoing or liability as to the Company, or of the appropriateness of a class action in such litigation.
As of September 30, 2018, the Company was not a party to any other legal proceedings that were expected, individually or in the aggregate, to have a material adverse effect on its business, financial condition, or operating results.

Off-Balance Sheet Commitments

Unconditional Purchase Obligations
The Company has contractual obligations with suppliers for unconditional annual minimum inventory purchases in the amounts of $31.3 million as of September 30, 2018.

Operating Leases
The Company leases various equipment and facilities. The Company does not currently utilize any other off-balance sheet financing arrangements. As of September 30, 2018, the Company's total future minimum lease payments under noncancelable operating leases were $10.2 million.

-24-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


14.    INTEREST AND OTHER (INCOME) EXPENSE, NET
Interest and other (income) expense, net, consisted of the following (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Interest income
$
(66
)
 
$
(41
)
 
$
(186
)
 
$
(122
)
Interest expense
89

 
81

 
231

 
156

Other (income) expense, net
(73
)
 
(46
)
 
(8
)
 
(220
)
Total interest and other (income) expense, net
$
(50
)
 
$
(6
)
 
$
37

 
$
(186
)
Cash paid for interest for the three months ended September 30, 2018 and 2017 was $58 thousand and $67 thousand, respectively. Cash paid for interest for the nine months ended September 30, 2018 and 2017 was $143 thousand and $125 thousand, respectively.
15.    CREDIT FACILITY
On July 27, 2017, we entered into a Credit Agreement (the "Credit Agreement") with JPMorgan Chase Bank, N.A. ("Chase"), which was amended by us on May 11, 2018 (the "Facility Amendment") to allow us the additional flexibility to make permitted investments, subject to agreed upon limitations. The Credit Agreement provides for a revolving credit facility up to $30.0 million (the "Credit Facility"), although the amount of the Credit Facility may be increased by an additional $20.0 million up to a total of $50.0 million subject to receipt of additional lender commitments and other conditions. Any interest on borrowings due is to be charged at either the (i) rate of interest per annum publicly announced from time to time by Chase as its prime rate in effect at its principal offices in New York City, subject to a floor, minus 1.65%, or (ii) the interest rate per annum equal to (a) LIBOR for the interest period in effect multiplied by (b) Chase's Statutory Reserve Rate (as defined in the Credit Agreement), plus 1.10% and payable monthly. There is an annual minimum interest charge of $60 thousand under the Credit Agreement. Borrowings under the Credit Facility are subject to certain financial and non-financial covenants and are available for various corporate purposes, including general working capital, capital investments, and certain permitted acquisitions and investments. The Credit Agreement also permits us to issue letters of credit. The maturity date of the Credit Facility is July 27, 2020. The foregoing discussion of the Credit Facility is a summary only and is qualified in its entirety by reference to the full text of the Credit Agreement, a copy of which has been filed as an exhibit to the Company's Current Report on Form 8-K filed with the SEC on August 2, 2017, and the Facility Amendment, a copy of which has been filed as an exhibit to the Company's Current Report on Form 10-Q filed with the SEC on August 8, 2018. At September 30, 2018, we had a $6.0 million line of credit outstanding under the Credit Facility and we were in compliance with all financial covenants.

-25-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)



16.    SEGMENT REPORTING
The Company is composed of two reportable segments, CCA and OVP. The CCA segment includes Point of Care diagnostic laboratory instruments and consumables, and Point of Care digital imaging diagnostic instruments and software services as well as single use diagnostic and other tests, pharmaceuticals and vaccines, primarily for canine and feline use. These products are sold directly by the Company as well as through independent third-party distributors and through other distribution relationships. CCA segment products manufactured at the Des Moines, Iowa production facility included in the OVP segment's assets are transferred at cost and are not recorded as revenue for the OVP segment. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle, but also for other animals including small mammals. All OVP products are sold by third parties under third-party labels.

Summarized financial information concerning the Company's reportable segments is shown in the following tables (in thousands):
Three Months Ended September 30, 2018
 
Core
Companion
Animal Health
 
Other Vaccines, Pharmaceuticals and Products
 
 
 
Total
Total revenue
 
$
27,190

 
$
3,765

 
$
30,955

Operating (loss) income
 
(4,402
)
 
807

 
(3,595
)
(Loss) income before income taxes
 
(4,352
)
 
807

 
(3,545
)
Capital expenditures
 
20

 
229

 
249

Depreciation and amortization
 
823

 
317

 
1,140

Three Months Ended September 30, 2017
 
Core
Companion
Animal Health
 
Other Vaccines, Pharmaceuticals and Products
 
 
 
Total
Total revenue
 
$
25,578

 
$
4,758

 
$
30,336

Operating income
 
3,068

 
710

 
3,778

Income before income taxes
 
3,074

 
710

 
3,784

Capital expenditures
 
34

 
669

 
703

Depreciation and amortization
 
935

 
259

 
1,194

Nine Months Ended September 30, 2018
 
Core
Companion
Animal Health
 
Other Vaccines, Pharmaceuticals and Products
 
 
 
Total
Total revenue
 
$
80,652

 
$
12,729

 
$
93,381

Operating Income
 
384

 
95

 
479

Income before income taxes
 
347

 
95

 
442

Capital expenditures
 
117

 
944

 
1,061

Depreciation and amortization
 
2,568

 
905

 
3,473



-26-


HESKA CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


Nine Months Ended September 30, 2017
 
Core
Companion
Animal Health
 
Other Vaccines, Pharmaceuticals and Products
 
 
 
Total
Total revenue
 
$
75,453

 
$
17,847

 
$
93,300

Operating income
 
6,763

 
4,363

 
11,126

Income before income taxes
 
6,971

 
4,341

 
11,312

Capital expenditures
 
119

 
1,879

 
1,998

Depreciation and amortization
 
2,837

 
749

 
3,586


Asset information by reportable segment as of September 30, 2018 is as follows (in thousands):
 
 
Core
Companion
Animal Health
 
Other Vaccines, Pharmaceuticals and Products
 
Total
Total assets
 
$
123,326

 
$
20,794

 
$
144,120

Net assets
 
87,050

 
24,551

 
111,601


Asset information by reportable segment as of December 31, 2017 is as follows (in thousands):
 
 
Core
Companion
Animal Health
 
Other Vaccines, Pharmaceuticals and Products
 
Total
Total assets
 
$
111,968

 
$
23,819

 
$
135,787

Net assets
 
75,984

 
24,456

 
100,440




-27-




Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and related Notes included in Part I Item 1 of this Form 10-Q.
This discussion contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Rule 175 promulgated thereunder, that involve risks and uncertainties. Such statements, which include statements concerning future revenue sources and concentration, gross profit margins, selling and marketing expenses, remaining minimum performance obligations, research and development expenses, general and administrative expenses, capital resources, additional financings or borrowings and additional losses, are subject to risks and uncertainties, including, but not limited to, those discussed in "Risk Factors" in Item 1A in Part I of our Annual Report on Form 10-K/A for the year ended December 31, 2017 that could cause actual results to differ materially from those projected. The Risk Factors and others described in the Company’s periodic and current reports filed with the SEC from time to time are not necessarily all of the important factors that could cause the Company’s actual results to differ materially from those projected. Other unknown or unpredictable factors could also harm the Company’s results. The forward-looking statements set forth in this Form 10-Q are as of the close of business on November 6, 2018 and we undertake no duty and do not intend to update this information, except as required by applicable laws. If we updated one or more forward looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above.
Overview
We sell advanced veterinary diagnostic and specialty products. Our offerings include Point of Care diagnostics laboratory instruments and consumables, Point of Care digital imaging diagnostic products, vaccines, local and cloud-based data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. Our core focus is on supporting veterinarians in the canine and feline healthcare space.
Our business is composed of two reportable segments, CCA and OVP. The CCA segment includes, primarily for canine and feline use, Point of Care laboratory instruments and consumables, digital imaging diagnostic instruments, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle but also for other species including equine, porcine, avian, feline and canine. OVP products are sold by third parties under third party labels.
The CCA segment represented 88% and 86% of our revenue for the three and nine months ended September 30, 2018, respectively. The OVP segment represented 12% and 14% of our revenue for the three and nine months ended September 30, 2018, respectively.
CCA Segment
Revenue from Point of Care laboratory represented 54% of CCA revenue for the three and nine months ended September 30, 2018. Revenue from this area primarily involves placing an instrument under contract in the field and generating future revenue from testing consumables, such as cartridges and reagents, as that instrument is used. The majority of revenue from Point of Care laboratory results from the sales of such testing consumables to an installed base of instruments, followed by instrument sales and other revenue

-28-




sources such as service and repairs. Instruments placed under subscription agreements are considered operating or sales-type leases, depending on the duration and other factors of the underlying agreement. A loss of, or disruption in, the procurement of consumables we are selling to an installed base of instruments could substantially harm our business. All of our Point of Care laboratory and other non-imaging instruments and consumables are supplied by third parties, who typically own the product rights and supply the product to us under marketing and/or distribution agreements. In many cases, we have collaborated with a third party to adapt a human instrument for veterinary use. Major products in this area include our instruments for chemistry, hematology, blood gas, coagulation and immunodiagnostic testing and their affiliated operating consumables.
Point of Care Imaging hardware, software and services represented approximately 20% of CCA revenue for the three and nine months ended September 30, 2018. Digital radiography is the largest product offering in this area, which also includes ultrasound instruments. Digital radiography solutions typically consist of a combination of hardware and software placed with a customer, often combined with an ongoing service and support contract. We sell our imaging solutions both in the United States and internationally. Our experience has been that most of the revenue is generated at the time of sale in this area, in contrast to the Point of Care diagnostic laboratory placements discussed above where ongoing consumable revenue is often a larger component of economic value as a given instrument is used.
Other CCA revenue, including single use diagnostic and other tests, pharmaceuticals and biologicals as well as research and development, licensing and royalty revenue, represented 26% of CCA revenue for the three and nine months ended September 30, 2018. Since items in this area are often single use by their nature, our typical aim is to build customer satisfaction and loyalty for each product, generate repeat annual sales from existing customers and expand our customer base in the future. Products in this area are both supplied by third parties and provided by us. Major products and services in this area include heartworm diagnostic tests and preventives, and allergy test kits, allergy immunotherapy and testing.
We consider the CCA segment to be our core business and devote most of our management time and other resources to improving the prospects for this segment. Maintaining a continuing, reliable and economic supply of products we currently obtain from third parties is critical to our success in this area. Virtually all of our sales and marketing expenses occur in the CCA segment. The majority of our research and development spending is dedicated to this segment as well.
All of our CCA products are ultimately sold primarily to or through veterinarians. In many cases, veterinarians will mark up their costs to their customer. The acceptance of our products by veterinarians is critical to our success. CCA products are sold directly to end users by us as well as through distribution relationships, such as our agreement with Merck Animal Health, the sale of kits to conduct blood testing to third-party veterinary diagnostic laboratories and independent third-party distributors. Revenue from direct sales and distribution relationships represented approximately 51% and 49%, respectively, of CCA revenue for the three months ended September 30, 2018, and approximately 52% and 48%, respectively, of CCA revenue for the nine months ended September 30, 2018.
OVP Segment
The OVP segment includes our 168,000 square foot USDA and FDA licensed production facility in Des Moines, Iowa. We view this facility as an asset which could allow us to control our cost of goods on any pharmaceuticals and vaccines that we may commercialize in the future. We have increased integration of this facility with our operations elsewhere. For example, virtually all our U.S. inventory, excluding our imaging products, is now stored at this facility and related fulfillment logistics are managed there. CCA segment products manufactured at this facility are transferred at cost and are not recorded as revenue for our OVP

-29-




segment. We view OVP reported revenue as revenue primarily to cover the overhead costs of the facility and to generate incremental cash flow to fund our CCA segment.
Historically, a significant portion of our OVP segment's revenue has been generated from the sale of certain bovine vaccines, which have been sold primarily under the Titanium® and MasterGuard® brands. We have an agreement with Elanco Inc. for the production of these vaccines (the "Elanco Agreement"). Our OVP segment also produces vaccines and pharmaceuticals for other third parties.
Results of Operations
Our analysis presented below is organized to provide the information we believe will facilitate an understanding of our historical performance and relevant trends going forward.
The following tables set forth, for the periods indicated, certain data derived from our unaudited Condensed Consolidated Statements of Income (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Revenue
$
30,955

 
$
30,336

 
$
93,381

 
$
93,300

Gross profit
14,794

 
13,553

 
41,166

 
41,691

Operating expenses
18,389

 
9,775

 
40,687

 
30,565

Operating (loss) income
(3,595
)
 
3,778

 
479

 
11,126

Interest and other (income) expense, net
(50
)
 
(6
)
 
37

 
(186
)
(Loss) income before income taxes
(3,545
)
 
3,784

 
442

 
11,312

Income tax (benefit) expense
(1,875
)
 
701

 
(1,941
)
 
787

Net (loss) income
(1,670
)
 
3,083

 
2,383

 
10,525

Net loss attributable to non-controlling interest

 

 

 
(498
)
Net (loss) income attributable to Heska
$
(1,670
)
 
$
3,083

 
$
2,383

 
$
11,023


CCA Segment
 
Three Months Ended September 30,
 
Change
 
2018
 
2017
 
Dollar
 Change
 
%
 Change
Point of Care Laboratory:
$
14,584

 
$
13,805

 
$
779

 
6
 %
      Consumables
11,598

 
9,773

 
1,825

 
19
 %
      Instruments
2,610

 
3,456

 
(846
)
 
(24
)%
      Other
376

 
576

 
(200
)
 
(35
)%
Point of Care Imaging
5,326

 
4,285

 
1,041

 
24
 %
Other CCA Revenue
7,280

 
7,488

 
(208
)
 
(3
)%
Total CCA Revenue
$
27,190

 
$
25,578

 
$
1,612

 
6
 %
Percent of total revenue
87.8
%
 
84.3
%
 
 
 
 
Cost of revenue
13,758

 
13,295

 
463

 
3
 %
Gross profit
13,432

 
12,283

 
1,149

 
9
 %
Operating (loss) income
$
(4,402
)
 
$
3,068

 
$
(7,470
)
 
(243
)%

-30-




 
Nine Months Ended September 30,
 
Change
 
2018
 
2017
 
Dollar
Change
 
%
Change
Point of Care Laboratory:
$
43,277

 
$
40,735

 
$
2,542

 
6
 %
      Consumables
33,942

 
28,933

 
5,009

 
17
 %
      Instruments
8,087

 
10,250

 
(2,163
)
 
(21
)%
      Other
1,248

 
1,552

 
(304
)
 
(20
)%
Point of Care Imaging
15,759

 
13,643

 
2,116

 
16
 %
Other CCA Revenue
21,616